Publications by authors named "D Deremer"
Article Synopsis
- BAP1 mutations lead to a loss of function affecting cell cycle and DNA repair, making patients potentially responsive to PARP inhibitors like niraparib.
- A phase II trial evaluated niraparib in patients with advanced tumors likely to have mBAP1 mutations, focusing on response rates, progression-free survival, and overall survival.
- Despite not meeting the primary efficacy goal, some clinical benefits were observed in patients with confirmed mBAP1 mutations, suggesting the need for further research.
The University of Florida Health conducted a pragmatic implementation of a pharmacogenetics (PGx) panel-based test to guide medications used for supportive care prescribed to patients undergoing chemotherapy. The implementation was in the context of a pragmatic clinical trial for patients with non-hematologic cancers being treated with chemotherapy. Patients were randomized to either the intervention arm or control arm and received PGx testing immediately or at the end of the study, respectively.
View Article and Find Full Text PDFArticle Synopsis
- The objective of this review is to assess capivasertib's pharmacology, efficacy, and safety for treating advanced breast cancer patients who are hormone receptor-positive and HER2-negative, particularly those with specific genetic alterations like PIK3CA and AKT1.
- Capivasertib is a pioneering drug that inhibits key AKT isoforms in the PI3K/AKT/mTOR pathway and has shown improved progression-free survival in trials, especially when combined with fulvestrant, compared to a placebo.
- This drug offers a promising option for patients who have not responded to previous treatments, demonstrating manageable side effects and potential for integration into standard care practices for advanced breast cancer.
Background: Supportive care medication use differences may contribute to racial disparities observed in health-related quality of life in patients with pancreatic cancer.
Methods: In this observation study using the Surveillance, Epidemiology, and End Results-Medicare linked database, we sought to examine supportive care medication use disparities in patients with pancreatic cancer from 2005 to 2017 by race and ethnicity.
Results: Among 74,309 patients included in the final analysis, racial and ethnic disparities in the use of supportive care medications were identified.